Clinical Advisors

ViaCyte’s clinical advisors represent a group of internationally-renowned physicians with extensive experience developing new treatment options for patients with diabetes.  The Clinical Advisory Board helps to advance the Company’s multiple, clinical-stage program.

Orville G. Kolterman, M.D.

Orville G. Kolterman, M.D.

Chief Medical Officer at Whole Biome Inc.; former Senior Vice President & Chief Medical Officer, Amylin Pharmaceuticals

Orville G. Kolterman, M.D. is the chief medical officer of Whole Biome Inc. Prior to that, Dr. Kolterman joined Amylin in 1992 and served as Senior Vice President, Clinical Affairs and Senior Vice President, Regulatory Affairs until 2012, when the company was acquired by AstraZeneca and Bristol-Myers Squibb. Dr. Kolterman was instrumental in the development of Amylin’s first-in-class diabetes medicines, SYMLIN (pramlintide acetate) injection and BYETTA (exenatide) injection. Prior to Amylin, Dr. Kolterman was Program Director of the General Clinical Research Center and Medical Director of the Diabetes Center at the UC San Diego Medical Center. He has also served as Assistant Professor of Medicine in the Endocrinology and Metabolism Division at the University of Colorado School of Medicine, Denver and was a member of the Diabetes Control and Complications Trial Study Group. Dr. Kolterman currently serves as a consultant to the Epidemiology of Diabetes Intervention and Complications Study. Dr. Kolterman received his M.D. from Stanford University School of Medicine.

Jay S. Skyler, M.D.

Jay S. Skyler, M.D.

Professor of Medicine, Pediatrics, and Psychology, University of Miami Miller School of Medicine and Deputy Director for Clinical Research and Academic Programs at the Diabetes Research Institute

Jay S. Skyler, M.D., MACP, is a professor of Medicine, Pediatrics, and Psychology in the Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida. He served as director of that Division from 2000 to 2004. At the University of Miami, he is deputy director for Clinical Research and Academic Programs in the Diabetes Research Institute. For 22 years, Dr. Skyler served as chairman of the NIH (NIDDK)-sponsored Type 1 Diabetes TrialNet, an international network conducting clinical trials to prevent type 1 diabetes or interdict the type 1 diabetes disease process. His research interests are in clinical aspects of diabetes, particularly improving the care of type 1 diabetes through meticulous glycemic control, psychosocial and behavioral support, and immune system intervention. He is widely acclaimed for developing “algorithms” for patient adjustment of insulin doses. Dr. Skyler is a past president of the American Diabetes Association, the International Diabetes Immunotherapy Group, and the Southern Society for Clinical Investigation, and was a vice president of the International Diabetes Federation. He served as a member of the Endocrinology, Diabetes, and Metabolism Subspecialty Examining Board of the American Board of Internal Medicine, as chairman of the Council of Subspecialty Societies of the American College of Physicians (ACP) and a member of the ACP Board of Regents. He was founding editor-in-chief of Diabetes Care and currently is senior editor of Diabetes Technology & Therapeutics. He has a B.S. from Pennsylvania State University and a M.D. from Jefferson Medical College. He served as an intern, resident, and fellow, and was on the faculty of Duke University.

James S. Shapiro, M.D., Ph.D.

James S. Shapiro, M.D., Ph.D.

Canada Research Chair, Director of the Clinical Islet and Liver Transplant Programs at the University of Alberta of Edmonton, Canada

James Shapiro, M.D., Ph.D. is Professor of Surgery, Medicine and Surgical Oncology, and Director of the Clinical Islet and Living Donor Liver Transplant Programs at the University of Alberta in Edmonton, Canada. He directs one of the leading clinical islet transplant programs worldwide with hundreds of patients treated and was the lead investigator of the team that developed the “Edmonton Protocol,” the first trial to achieve consistent 100% insulin independence in islet-alone transplant recipients with type 1 diabetes. Dr. Shapiro subsequently led the trial which replicated these findings in nine international centers. He has an active experimental laboratory working on improving long term survival of transplanted islets and in immunomodulation of transplanted tissues. Dr. Shapiro is fellow of the Royal Society of Canada and has received several prestigious awards, including the Hunterian Medal from the Royal College of Surgeons of England, the Paul E. Lacy Gold Medal, the Gold Medal in Surgery from the Royal College of Physicians and Surgeons of Canada, the Governor General’s Gold Medal, the Queen’s Jubilee Medal, the Meritorious Service Medal. He obtained his M.D. at the University of Newcastle-upon-Tyne and trained in surgery at the University of Bristol, UK.

Daniel Pipeleers, M.D., Ph.D.

Daniel Pipeleers, M.D., Ph.D.

Director, Diabetes Research Center, Free University of Brussels, Belgium

Daniel Pipeleers, M.D., Ph.D. is the director of the Diabetes Research Center at the Free University of Brussels. Since 2002, he has been the director of the The Center for Beta Cell Therapy in Diabetes. He founded two networks for clinical translation, the Belgian Diabetes Registry with associated Diabetes Biobank and the international Beta Cell Therapy Consortium, supported by grants from the European Commission and JDRF. Since 1990, he has been the director of the VUB-Diabetes Research Center, where expertise in beta cell biology, pathology, and therapy guides strategies and trials for early diagnosis, prevention, and treatment of type 1 diabetes. Since 1980, he has been a professor at Vrije Universiteit Brussel-VUB and since 1987, a consultant at University Hospital, Brussels. Between 1971 and 1980, he was an investigator at the Belgian Research Foundation and Harkness Fellow Commonwealth Foundation at Université Libre de Bruxelles, Washington University St Louis, Queen Elisabeth Foundation Brussels. Dr. Pipeleers is an Honorary Doctor at Uppsala University, Sweden, member of the Belgian Royal Academy of Medicine, recipient of twelve international and national awards in medical sciences. He has served as a board member and advisor in academic, clinical, and governmental institutions in scientific and bioindustrial organizations.

Christophe Arbet-Engels, M.D., Ph.D., M.B.A.

Christophe Arbet-Engels, M.D., Ph.D., M.B.A.

Chief Medical Officer at Neurogastrx

Christophe Arbet-Engels, M.D., Ph.D., M.B.A. is Chief Medical Officer at Neurogastrx with more than 25 years of experience in life sciences, academia, and industry. After his work at the Salk Institute for Biological Studies, Dr. Arbet-Engels has served in senior leadership roles for programs with a focus in diabetes-metabolism and led programs, in complex global and local settings, ranging from diabetes, cardiovascular-metabolism, neurology, orphan diseases to oncology. His leadership encompassed clinical development and registration, launch and lifecycle management for several innovative drugs for the treatment of diabetes, metabolism, and cardiovascular diseases, including Lantus® (insulin glargine) and Jardiance® (empagliflozin).
Dr. Arbet-Engels worked in biotech companies such as Poxel Pharmaceuticals and Ligand Pharmaceuticals, as well as large pharma including, Biogen, Boehringer Ingelheim, Roche and Aventis (now Sanofi). In addition, he provided expertise to the Gerson Lehrman Group, and worked as French Foreign Trade Advisor for the French Government to advise and support French or other startup companies develop their business in the U.S. Currently, Dr. Arbet-Engels is a Member of the Board of Tutors in Biochemical Sciences at Harvard University.
Dr. Arbet-Engels has a medical degree from University of Paris Sud, a Ph.D. in endocrinology/diabetes and metabolism from Paris Descartes University and a master’s degree in business administration from Rutgers University.

Alan Moses, MD

Alan Moses, MD

Independent consultant for the pharmaceutical and biotechnology sector

Trained in internal medicine and endocrinology, Dr. Alan Moses spent the early part of his academic career at Harvard doing bench and clinical research and clinical care. Dr. Moses co-founded and directed the Clinical Investigator Training Program at Beth Israel Deaconess-Harvard Medical School-MIT. From 1998 to 2004, Dr. Moses served as Senior Vice President and Chief Medical Officer of the Joslin Diabetes Center with specific responsibility for the Joslin Clinic. He joined Novo Nordisk in 2004. During his 14 years at Novo Nordisk, Dr. Moses served in multiple roles beginning as Associate Vice President of Medical Affairs in the U.S. and rising to the position of Senior Vice President and Global Chief Medical Officer working in Copenhagen.
Dr. Moses earned his M.D. from the Washington University School of Medicine in St. Louis, worked for three years at the National Institutes of Health, completed his clinical endocrine/diabetes training at Tufts New England Medical Center, and studied Health Care Strategy at Harvard Business School. He retired from Novo Nordisk in June 2018.